109 related articles for article (PubMed ID: 25556921)
41. Massive dissemination of adult glioblastomas.
Willard N; Kleinschmidt-DeMasters BK
Clin Neuropathol; 2015; 34(6):330-42. PubMed ID: 26308254
[TBL] [Abstract][Full Text] [Related]
42. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
[TBL] [Abstract][Full Text] [Related]
43. From GWAS risk foci to glioma molecular subclass.
Yung WK
Neuro Oncol; 2013 May; 15(5):513-4. PubMed ID: 23620433
[No Abstract] [Full Text] [Related]
44. Mutation-based clustering and classification analysis reveals distinctive age groups and age-related biomarkers for glioma.
Jean-Quartier C; Jeanquartier F; Ridvan A; Kargl M; Mirza T; Stangl T; Markaĉ R; Jurada M; Holzinger A
BMC Med Inform Decis Mak; 2021 Feb; 21(1):77. PubMed ID: 33639927
[TBL] [Abstract][Full Text] [Related]
45. Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics.
Hench J; Bihl M; Bratic Hench I; Hoffmann P; Tolnay M; Bösch Al Jadooa N; Mariani L; Capper D; Frank S
Neuro Oncol; 2018 Nov; 20(12):1682-1683. PubMed ID: 30169880
[No Abstract] [Full Text] [Related]
46. Isocitrate dehydrogenase mutations: A biomarker for glioma-related excitability and seizures.
Wychowski T; Kapur J
Neurology; 2017 May; 88(19):1782-1783. PubMed ID: 28404804
[No Abstract] [Full Text] [Related]
47. [The IDH1/2 biomarker in tumor pathology].
Lehmann U; Stenzinger A
Pathologie (Heidelb); 2023 Sep; 44(5):318-319. PubMed ID: 37249659
[No Abstract] [Full Text] [Related]
48. On gliomas masquerading as other disorders.
ASK-UPMARK E
Acta Med Scand; 1960 Aug; 167():369-76. PubMed ID: 13684772
[No Abstract] [Full Text] [Related]
49. Reply: To PMID 23219067.
Jakobiec FA; Grossniklaus HE
Am J Ophthalmol; 2013 Jul; 156(1):203. PubMed ID: 23791373
[No Abstract] [Full Text] [Related]
50. An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas.
Gregory TA; Williford GL; Maronge JM; Alfaro K; Fuller GN; de Groot J; Puduvalli VK; Ballester LY; Majd NK
Neuro Oncol; 2023 Apr; 25(4):808-809. PubMed ID: 36723868
[No Abstract] [Full Text] [Related]
51. [Rapid immunohistochemistry for brain tumor].
Nanjo H; Hiroshima Y; Minamiya Y; Sasajima T; Nakamura R; Akagami Y
Nihon Rinsho; 2016 Sep; 74 Suppl 7():495-500. PubMed ID: 30634802
[No Abstract] [Full Text] [Related]
52. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
53. Cancer stem cells in glioblastoma.
Lathia JD; Mack SC; Mulkearns-Hubert EE; Valentim CL; Rich JN
Genes Dev; 2015 Jun; 29(12):1203-17. PubMed ID: 26109046
[TBL] [Abstract][Full Text] [Related]
54. Novel molecular insights from routine genotyping of colorectal carcinomas.
Stachler MD; Rinehart E; Lindeman N; Odze R; Srivastava A
Hum Pathol; 2015 Apr; 46(4):507-13. PubMed ID: 25683705
[TBL] [Abstract][Full Text] [Related]
55. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Goswami RS; Patel KP; Singh RR; Meric-Bernstam F; Kopetz ES; Subbiah V; Alvarez RH; Davies MA; Jabbar KJ; Roy-Chowdhuri S; Lazar AJ; Medeiros LJ; Broaddus RR; Luthra R; Routbort MJ
Clin Cancer Res; 2015 Jun; 21(11):2644-51. PubMed ID: 25695693
[TBL] [Abstract][Full Text] [Related]
56. Molecular pathology of colorectal cancer.
Bosman F; Yan P
Pol J Pathol; 2014 Dec; 65(4):257-66. PubMed ID: 25693079
[TBL] [Abstract][Full Text] [Related]
57. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
58. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.
Dimitrov L; Hong CS; Yang C; Zhuang Z; Heiss JD
Int J Med Sci; 2015; 12(3):201-13. PubMed ID: 25678837
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
Takano S; Kato Y; Yamamoto T; Liu X; Ishikawa E; Kaneko MK; Ogasawara S; Matsuda M; Noguchi M; Matsumura A
Brain Tumor Pathol; 2015 Jul; 32(3):169-75. PubMed ID: 25652153
[TBL] [Abstract][Full Text] [Related]
60. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL
Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
